You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0431 Sustained Improvements in Skin Symptoms, Physical Functioning, and Quality of Life with Secukinumab versus Ustekinumab in Patients with Moderate-To-Severe Psoriasis and Concomitant Psoriatic Arthritis: 52 Week Results from The Clear Study

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Psoriatic arthritis
THU0431 Sustained Improvements in Skin Symptoms, Physical Functioning, and Quality of Life with Secukinumab versus Ustekinumab in Patients with Moderate-To-Severe Psoriasis and Concomitant Psoriatic Arthritis: 52 Week Results from The Clear Study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gottlieb A, Thaçi D, Blauvelt A, et al
THU0431 Sustained Improvements in Skin Symptoms, Physical Functioning, and Quality of Life with Secukinumab versus Ustekinumab in Patients with Moderate-To-Severe Psoriasis and Concomitant Psoriatic Arthritis: 52 Week Results from The Clear Study
Annals of the Rheumatic Diseases 2016;75:345-346.